Skip to main content

Recent advances and limitations in the application of kahalalides for the control of cancer

Author(s): Wyer, Scott; Townsend, Danyelle M; Ye, Zhiwei; Kourtidis, Antonis; Choo, Yeun-Mun; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1901zf9q
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWyer, Scott-
dc.contributor.authorTownsend, Danyelle M-
dc.contributor.authorYe, Zhiwei-
dc.contributor.authorKourtidis, Antonis-
dc.contributor.authorChoo, Yeun-Mun-
dc.contributor.authorde Barros, André Luís Branco-
dc.contributor.authorDonia, Mohamed S-
dc.contributor.authorHamann, Mark T-
dc.date.accessioned2023-12-08T18:45:51Z-
dc.date.available2023-12-08T18:45:51Z-
dc.date.issued2022-04en_US
dc.identifier.issn0753-3322-
dc.identifier.urihttp://arks.princeton.edu/ark:/88435/pr1901zf9q-
dc.description.abstractSince the discovery of the kahalalide family of marine depsipeptides in 1993, considerable work has been done to develop these compounds as new and biologically distinct anti-cancer agents. Clinical trials and laboratory research have yielded a wealth of data that indicates tolerance of kahalalides in healthy cells and selective activity against diseased cells. Currently, two molecules have attracted the greates level of attention, kahalalide F (KF) and isokahalalide F (isoKF, Irvalec, PM 02734, elisidepsin). Both compounds were originally isolated from the sarcoglossan mollusk Elysia rufescens but due to distinct structural characteristics it has been hypothesized and recently shown that the ultimate origin of the molecules is microbial. The search for their true source has been a subject of considerable research in the anticipation of finding new analogs and a culturable expression system that can produce sufficient material through fermentation to be industrially relevant.en_US
dc.languageenen_US
dc.language.isoen_USen_US
dc.relation.ispartofBiomedicine & Pharmacotherapyen_US
dc.rightsAuthor's manuscripten_US
dc.subject16SrRNA; Akt; Anti-psoriatic; Bryopsis ; Cancer; Cytochrome c oxidase I; Cytotoxicity; Depsipeptide; Elisidepsin; ErbB; GLPORYx; Her2; Her3; Isokahalalide; Kahalalide A; Kahalalide G; Kahalalide; MAPK; Mollusk; Oncosisen_US
dc.titleRecent advances and limitations in the application of kahalalides for the control of canceren_US
dc.typeJournal Articleen_US
dc.identifier.doidoi:10.1016/j.biopha.2022.112676-
pu.type.symplectichttp://www.symplectic.co.uk/publications/atom-terms/1.0/journal-articleen_US

Files in This Item:
File Description SizeFormat 
recent_advances_control_of_cancer.pdf1.8 MBAdobe PDFView/Download


Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.